Yes, you can breastfeed while taking glycopyrrolate.
Glycopyrrolate (glycopyrronium) is compatible with breastfeeding and does not require interruption of nursing. 1
Why Glycopyrrolate is Safe During Breastfeeding
Pharmacologic Properties Favor Safety
Glycopyrrolate is a quaternary ammonium compound with several characteristics that minimize infant exposure 1:
- Poor lipid solubility - does not readily cross into breast milk
- Does not cross the blood-brain barrier - limited central nervous system effects
- Poor oral bioavailability (approximately 3%) - even if small amounts reach the infant through milk, absorption from the infant's gastrointestinal tract is minimal 2
- Ionized at physiological pH - further limiting transfer into milk
Guideline Recommendation
The 2020 Association of Anaesthetists guideline explicitly states that glycopyrronium is the "probably preferred antimuscarinic" and is "compatible with breastfeeding" 1. This is the most recent and authoritative guideline addressing this question.
Comparison to Atropine
While atropine (a tertiary amine) can be found in trace concentrations in breast milk and may theoretically inhibit lactation, glycopyrrolate's quaternary structure makes it far less likely to transfer into milk or affect the infant 1.
Important Caveats
FDA Labeling Acknowledges Data Limitations
The FDA label states: "There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production" 2. However, this reflects absence of specific human lactation studies rather than evidence of harm.
Clinical Decision-Making
The FDA label appropriately notes: "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for glycopyrrolate oral solution and any potential adverse effects on the breastfed infant" 2.
Practical Guidance
- No need to pump and dump or interrupt breastfeeding
- No waiting period required after administration
- The chemical properties of glycopyrrolate make clinically significant infant exposure highly unlikely
- Monitor infant for any unusual symptoms (though adverse effects are not expected based on the drug's properties)
The convergence of pharmacologic principles, expert guideline recommendations, and the drug's molecular characteristics all support the safety of breastfeeding while taking glycopyrrolate 1, 2.